Shandong Jincheng Pharmaceutical Group (300233) Fundamentals 2026 — P/E 71.8x, Revenue Analysis | SniperIQ
Shandong Jincheng Pharmaceutical Group (300233) is a CN-listed Basic Materials company in Chemicals with a market capitalization of ¥4.7B, trading at ¥12.50 on the SHZ. This SniperIQ fundamentals page covers Shandong Jincheng Pharmaceutical Group's valuation (P/E 71.8x, P/B 1.3x), profitability (net margin 2.4%), revenue (¥2.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Jincheng Pharmaceutical Group's market cap?
Shandong Jincheng Pharmaceutical Group (300233) has a market capitalization of approximately ¥4.7B, trading at ¥12.50 on the SHZ. Market cap moves with the live share price.
What is Shandong Jincheng Pharmaceutical Group's P/E ratio?
Shandong Jincheng Pharmaceutical Group's trailing twelve-month P/E ratio is 71.8x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Shandong Jincheng Pharmaceutical Group?
Shandong Jincheng Pharmaceutical Group runs a net profit margin of 2.4%, a gross margin of 35.0%, and an operating margin of 4.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Jincheng Pharmaceutical Group generate?
Shandong Jincheng Pharmaceutical Group reported revenue of ¥2.7B for fiscal year 2025, with net income of ¥44M and earnings per share (EPS) of 0.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Jincheng Pharmaceutical Group pay a dividend?
Shandong Jincheng Pharmaceutical Group offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Jincheng Pharmaceutical Group financially healthy?
Shandong Jincheng Pharmaceutical Group carries a debt-to-equity ratio of 0.13x and a current ratio of 1.73x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Jincheng Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Jincheng Pharmaceutical Group (300233) the key facts are: market cap ¥4.7B, P/E 71.8x, revenue ¥2.7B, 52-week range 11.58-22.47. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Shandong Jincheng Pharmaceutical Group's full fundamentals live
Get Shandong Jincheng Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.